Congress needs to act to bring needed reforms into the 340B to make revenue from the drug pricing program more transparent and to ensure patients are benefitting from the discounts, according to a report released by Sen. Bill Cassidy, R-La., chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee.
Reforms are needed in the 340B drug program, Senate report says
